Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome

Clearmind Medicine Inc. and SciSparc Ltd. have partnered to conduct a study on the combination treatment of obesity and metabolic syndrome, using Clearmind's MEAI and SciSparc's Palmitoylethanolamide (PEA). The research agreement has been entered into with the Hebrew University of Jerusalem, led by Professor Joseph Tam. A previous pre-clinical study showed that obese animals treated with MEAI de..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 19.
  • textsms

MindRank Announces First-in-Human Phase 1 Study of MDR-001 in China

Clinical stage AI drug discovery company, MindRank, has announced the start of its first-in-human (FIH) Phase 1 study of MDR-001 in China. The proprietary glucagon-like peptide 1 receptor agonist (GLP-1 RA), which is an oral small-molecule designed to treat obesity and type 2 diabetes mellitus (T2DM), was discovered using MindRank's Molecule Pro AI platform. The FIH Phase 1 trial will evaluate t..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 15.
  • textsms

Eccogene Raises CNY 180 Million in Series B Equity Financing for Treatments of Metabolic Diseases

Clinical-stage biotech company Eccogene has raised CNY180m ($25m) in series B equity financing to support the development of its clinical-stage pipeline. The funding round was led by New Alliance Capital and Zhangjiang Healthcare Venture Capital, and included new investors Rockbleu Capital, YuFu Investment, Huajin Capital and Elikon Venture, as well as existing backers Delos Capital, Oriza Seed ..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 13.
  • textsms